Chongqing Zhifei Bio Products (300122) — Financial Flexibility Index
Chongqing Zhifei Bio Products (300122) has a Financial Flexibility Index of 0.10x as of September 2025. Free cash flow of CN¥1.62 Billion (operating CF CN¥1.42 Billion minus capex CN¥202.94 Million) represents 0% of total liabilities (CN¥16.79 Billion). Check Chongqing Zhifei Bio Products strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Chongqing Zhifei Bio Products Financial Flexibility Index (2007–2025)
Historical Financial Flexibility Index trend for Chongqing Zhifei Bio Products across 19 annual periods. See working capital position of Chongqing Zhifei Bio Products to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Chongqing Zhifei Bio Products (2007–2025)
Year-by-year free cash flow to debt coverage for Chongqing Zhifei Bio Products. For the full company profile including market capitalisation, see 300122 company net worth.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.37x | CN¥5.79 Billion | CN¥5.17 Billion | CN¥15.61 Billion | ▲ +303.0% |
| 2024 | -0.18x | CN¥-3.48 Billion | CN¥-4.41 Billion | CN¥19.08 Billion | ▼ -133.8% |
| 2023 | 0.54x | CN¥10.13 Billion | CN¥9.00 Billion | CN¥18.73 Billion | ▲ +116.4% |
| 2022 | 0.25x | CN¥3.44 Billion | CN¥1.99 Billion | CN¥13.77 Billion | ▼ -70.3% |
| 2021 | 0.84x | CN¥10.44 Billion | CN¥8.51 Billion | CN¥12.39 Billion | ▲ +35.9% |
| 2020 | 0.62x | CN¥4.32 Billion | CN¥3.50 Billion | CN¥6.97 Billion | ▲ +66.1% |
| 2019 | 0.37x | CN¥1.94 Billion | CN¥1.37 Billion | CN¥5.20 Billion | ▼ -7.8% |
| 2018 | 0.41x | CN¥1.07 Billion | CN¥585.59 Million | CN¥2.63 Billion | ▲ +9.0% |
| 2017 | 0.37x | CN¥434.46 Million | CN¥203.61 Million | CN¥1.17 Billion | ▼ -82.4% |
| 2016 | 2.11x | CN¥398.00 Million | CN¥89.95 Million | CN¥188.21 Million | ▼ 0.0% |
| 2015 | 2.11x | CN¥449.16 Million | CN¥223.45 Million | CN¥212.40 Million | ▲ +23.8% |
| 2014 | 1.71x | CN¥438.34 Million | CN¥161.39 Million | CN¥256.72 Million | ▼ -19.8% |
| 2013 | 2.13x | CN¥422.94 Million | CN¥221.58 Million | CN¥198.61 Million | ▼ -10.9% |
| 2012 | 2.39x | CN¥311.95 Million | CN¥112.89 Million | CN¥130.53 Million | ▼ -34.2% |
| 2011 | 3.63x | CN¥530.81 Million | CN¥221.25 Million | CN¥146.22 Million | ▲ +132.1% |
| 2010 | 1.56x | CN¥105.70 Million | CN¥54.19 Million | CN¥67.59 Million | ▼ -53.4% |
| 2009 | 3.35x | CN¥222.48 Million | CN¥210.61 Million | CN¥66.33 Million | ▲ +132.5% |
| 2008 | 1.44x | CN¥177.47 Million | CN¥141.58 Million | CN¥123.05 Million | ▲ +52.5% |
| 2007 | 0.95x | CN¥136.42 Million | CN¥111.66 Million | CN¥144.27 Million | — |